Will GnRH antagonists improve prostate cancer treatment?

This publication has 74 references indexed in Scilit:

• Rapid Suppression of Plasma Testosterone Levels and Tumor Growth in the Dunning Rat Model Treated with Degarelix, a New Gonadotropin-Releasing Hormone Antagonist
  The Journal of Pharmacology and Experimental Therapeutics, 2007
• Obesity and Sex Steroids during Gonadotropin-Releasing Hormone Agonist Treatment for Prostate Cancer
  Clinical Cancer Research, 2007
• Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic–pituitary–gonadal axis following treatment with GnRH analogues
  British Journal of Clinical Pharmacology, 2006
• Efficacy and Safety of Histrelin Subdermal Implant in Patients With Advanced Prostate Cancer
  Journal of Urology, 2006
• Multifaceted roles of β-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling
  Biochemical Journal, 2003
• Resistance to Luteinizing Hormone Releasing Hormone Agonist Therapy for Metastatic Prostate Cancer
  Journal of Urology, 2002
• Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice
  The Prostate, 1997
• Inhibition of growth of androgen-independent DU-145 prostate cancer in vivo by luteinising hormone-releasing hormone antagonist cetrorelix and bombesin antagonists RC-3940-II and RC-3950-II
  European Journal Of Cancer, 1997
• Desensitization of Gonadotropin-releasing Hormone Action in αT3-1 Cells Due to Uncoupling of Inositol 1,4,5-Trisphosphate Generation and Ca2+ Mobilization
  Published by Elsevier ,1996
• Antagonists of luteinizing hormone releasing hormone bind to rat mast cells and induce histamine release
  Inflammation Research, 1988